Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CytomX Therapeutics (CTMX) Other Non-Current Liabilities (2016 - 2025)

CytomX Therapeutics' Other Non-Current Liabilities history spans 9 years, with the latest figure at $4.4 million for Q4 2025.

  • For Q4 2025, Other Non-Current Liabilities rose 5.78% year-over-year to $4.4 million; the TTM value through Dec 2025 reached $4.4 million, up 5.78%, while the annual FY2025 figure was $4.4 million, 5.78% up from the prior year.
  • Other Non-Current Liabilities reached $4.4 million in Q4 2025 per CTMX's latest filing, up from $4.3 million in the prior quarter.
  • In the past five years, Other Non-Current Liabilities ranged from a high of $4.4 million in Q4 2025 to a low of $216000.0 in Q2 2023.
  • Average Other Non-Current Liabilities over 3 years is $3.6 million, with a median of $4.1 million recorded in 2024.
  • The largest YoY upside for Other Non-Current Liabilities was 1748.61% in 2024 against a maximum downside of 5.7% in 2024.
  • A 3-year view of Other Non-Current Liabilities shows it stood at $3.9 million in 2023, then rose by 5.7% to $4.1 million in 2024, then increased by 5.78% to $4.4 million in 2025.
  • Per Business Quant, the three most recent readings for CTMX's Other Non-Current Liabilities are $4.4 million (Q4 2025), $4.3 million (Q3 2025), and $4.2 million (Q2 2025).